# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k063131   
B. Purpose for Submission: New device   
C. Measurand: Carbamazepine and Valproic Acid   
D. Type of Test: Quantitative, homogenous enzyme immunoassay   
E. Applicant: Thermo Fisher Scientific Oy   
F. Proprietary and Established Names: Carbamezepine Valproic Acid TDM Calibration Set B   
G. Regulatory Information: 1. Regulation section: 21 CFR 862.3645, Neuroleptic drugs radioreceptor assay test system. (Carbamezepine and Valproic Acid) 21 CFR 862.3200, Calibrator Drug Mixture 2. Classification: II 3. Product code: KLT, Enzyme Immunoassay, Carbamazepine LEG, Enzyme Immunoassay, Valproic Acid DKB, Clinical Toxicology Calibrator 4. Panel: Toxicology (91)

# H. Intended Use:

1. Intended use(s): See Indications for use.

overdose and in monitoring levels of valproic acid to help ensure proper therapy. Calibrator   
TDM Calibration set B is intended for in vitro diagnostic use as a calibrator in the quantitative measurement of the kit code 981645 Carbamazepine and kit code 981650 Valproic acid assays on T60 Analyzer.

3. Special conditions for use statement(s): Prescription use

4. Special instrument requirements: T60 Clinical Chemistry Analyzers

# I. Device Description:

Carbamazepine The device consists of 4 reagents (Reagents A and B: buffer and lyophilizate).

# Reagent A:

buffer contains enzyme acceptor MOPS (3-(N-morpholino) propane sulfonic acid buffer, mouse monoclonal anti-carbamazepine antibodies, and ${ \mathrm { N a N } } _ { 3 }$ . lyophilizate contains enzyme acceptor (microbial), buffer salts and ${ \mathrm { N a N } } _ { 3 }$ .

# Reagent B:

buffer contains enzyme donor reconstitution MES (2-(N-morpholino) ethane sulfonic acid buffer and ${ \mathrm { N a N } } _ { 3 }$ .   
lyophilizate contains enzyme donor (microbial) conjugated to   
carbamazepine, Chlorophenol red- $\beta$ -D-galactopyranoside, buffer salts, and ${ \mathrm { N a N } } _ { 3 }$ .

Valproic Acid

The device consists of 4 reagents (Reagents A and B: buffer and lyophilizate)

# Reagent A:

• buffer contains enzyme acceptor HEPES - (N-[2-Hydroxyethyl] piperazine-N-[2-ethanesulfonic acid]) buffer) and ${ \mathrm { N a N } } _ { 3 }$ . lyophilizate contains enzyme acceptor (microbial), mouse monoclonal anti- valproic antibody, BSA, sodium salicylate, buffer salts, and ${ \mathrm { N a N } } _ { 3 }$ .

# Reagent B:

buffer contains enzyme donor reconstitution HEPES - (N-[2- Hydroxyethyl]piperazine-N-[2-ethanesulfonic acid]) buffer) and ${ \mathrm { N a N } } _ { 3 }$ . lyophilizate contains enzyme donor (microbial), conjugated to valproic acid, Chlorophenol red- $\cdot \beta$ -D-galactopyranoside, goat anti-mouse antibodies, buffer salts, and ${ \mathrm { N a N } } _ { 3 }$ .

# Calibrator

TDM Calibration set B consists of two levels of ready to use calibrators. The kit contains 1 vial/7.5 mL B0 calibrator and 1 vial/5.0 mL B1. These calibrators contain buffer salts, bovine serum albumin and $< 0 . 1 5 \%$ sodium azide; the B0 calibrator may also be used for dilution of high samples.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Cedia Carbamazepine II Cedia Valproic Acid II

Cedia DAU 5-Drug Calibrators

2. Predicate 510(k) number(s):

k914857   
k930734   
k935792

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Carbamazepine  Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Indications</td><td rowspan=1 colspan=1>Measurements are used inthe diagnosis andtreatment ofcarbamazepine overdoseand in monitoring levelsof carbamazepine toensure proper therapy.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>2 to 8°C.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>Quantitative,homogenous enzymeimmunoassay</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Carbamazepine  Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>T60 Clinical ChemistryAnalyzers</td><td rowspan=1 colspan=1>Roche Hitachi 911/912Analyzers</td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>1.0 to 19.0 µg/ml</td><td rowspan=1 colspan=1>0.5 to ~20 μg/ml</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum and Plasma</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Valproic Acid  Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Indications</td><td colspan="1" rowspan="1">Measurements are used inthe diagnosis andtreatment of valproic acidoverdose and inmonitoring levels ofvalproic acid to ensureproper therapy.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Technology</td><td colspan="1" rowspan="1">Quantitative,homogenous enzymeimmunoassay</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">2 to 8°C</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">Valproic Acid  Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">T60 Clinical ChemistryAnalyzers</td><td colspan="1" rowspan="1">Roche Hitachi 912</td></tr><tr><td colspan="1" rowspan="1">Range</td><td colspan="1" rowspan="1">3.0 µg/ml to 142.5 µg/ml</td><td colspan="1" rowspan="1">3.0 µg/ml to ~150 µg/ml</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Serum or Plasma</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI - Evaluation of Precision Performance of Clinical Chemistry Devices - EP05-A2 CLSI - Evaluation of the Linearity of Quantitative Analytical Methods - EP06-A CLSI - Method Comparison and Bias Estimation Using Patient Samples - EP09-A2

L. Test Principle:

The assays are based on the bacterial enzyme $\beta$ -galactosidase which has been genetically engineered into two inactive fragments. These spontaneously reassociate to form fully active enzyme that in the assay formats, cleaves a substrate, generating a color change that can be measured spectrophotometrically.

# M. Performance Characteristics (if/when applicable):

Analytical performance:

a. Precision/Reproducibility: Carbamazepine To evaluate precision, the within-lab and repeatability of the T60 Carbamazepine assay was calculated using the CLSI EP5-A2 method. Three commercially marketed controls (low, mid, high) were tested in duplicate during two runs per day over 21 days. The results are presented below:

<table><tr><td rowspan=1 colspan=1>MeanConcentration(μg/mL)</td><td rowspan=1 colspan=2>3.0</td><td rowspan=1 colspan=2>9.5</td><td rowspan=1 colspan=2>15.0</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Within-run</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>Between-run</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.42</td><td rowspan=1 colspan=1>2.8</td></tr></table>

Valproic Acid

To evaluate precision, the within-lab and repeatability of the T60 Valproic Acid assay was calculated using the CLSI EP5-A2 method. Three commercially marketed controls (low, mid, high) were tested in duplicate during two runs per day over 21 days. The results were as follows:

<table><tr><td rowspan=1 colspan=1>MeanConcentration(μg/mL)</td><td rowspan=1 colspan=2>35.0</td><td rowspan=1 colspan=2>81.1</td><td rowspan=1 colspan=2>113.6</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Within-run</td><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.81</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=1 colspan=1>Between-run</td><td rowspan=1 colspan=1>0.61</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.08</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.07</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>1.90</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>3.15</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>3.11</td><td rowspan=1 colspan=1>2.7</td></tr></table>

b. Linearity/assay reportable range:

# Carbamazepine

The linearity study was performed using CLSI EP6-A as a guideline. Dilution series were made from 7 human sera samples with low levels of carbamazepine spiked over a measured range of range of 1.2 to $1 8 . 9 \mathrm { u g / m L }$ and analyzed on a T60 analyzer. Four parallel measurements were made in random order. The study was performed with one reagent lot. Observed error was ${ \leq } 5 . 0 \%$ . The claimed measuring range is 1.0 to $1 9 . 0 \mathrm { u g / d L }$ .

# Valproic Acid

The linearity study was performed using CLSI EP6-A as a guideline. Dilution series were made from 9 human sera samples with low levels of valproic acid spiked over a measured range of range of 4.3 to $1 4 1 ~ \mathrm { u g / m L }$ and analyzed on a T60 analyzer. Four parallel measurements were made in random order. The study was performed with one reagent lot. Observed error was ${ \leq } 5 . 8 \%$ . The claimed reportable range for this assay is $3 . 0 { - } 1 4 2 . 5 ~ { \mu \mathrm { g / m L } }$ .

The package insert instructs customers to manually dilute (1:1) samples with TDM Calibrator B0 when results exceed the measuring range.

To validate the extended measurement range for carbamazepine, the sponsor used a high serum sample and made seven dilutions from the highest concentration down to normal human sera. The data support an extended range up to $3 7 . 5 ~ { \mu \mathrm { g / m l } }$ .

To validate the extended measuring range for valproic acid, the sponsor used a high serum sample and made eleven dilutions from the highest concentration down to normal human sera. The data support an extended range up to 282 $\mu \mathrm { g / m l }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods): The TDM B Calibrators are purchased from another manufacturer and relabeled. The TDM B Calibrator target values are determined using assay specific methods on the T60. The target value is the median of all values obtained and traceable to USP reference materials. The product stability claims are as follows: Open vial at $2 { - } 8 ^ { \circ } \mathrm { C }$ 60 days and Shelf life $2 { - } 8 ^ { \circ } \mathrm { C }$ 24 months.

# d. Detection limit

Carbamazepine

The lower limit of the assay (limit of blank - LOB) was determined by assaying 24 consecutive replicates of the analyte free (0 level) calibrator on the T60 Clinical Chemistry Analyzer. The LOB was calculated by multiplying the standard deviation by 3 and adding it to the absolute value of the mean. The limit of the blank was calculated to be $0 . 5 ~ \mathrm { u g / m L }$ .

The sponsor conducted a functional sensitivity study to determine the concentration at which acceptable assay precision is observed. A functional sensitivity study was performed using serum samples and the T60 Clinical Chemistry Analyzer. The functional sensitivity was defined as the lowest concentration that can be measured with an inter-assay CV of $20 \%$ . Serum samples were run in duplicates of 4 and the mean and SD were calculated based on the observed results. The sponsor claimed that the functional sensitivity of the candidate device is $1 . 0 \mathrm { u g / m L }$ , which is the lower limit of the measuring range.

# Valproic Acid

The limit of detection (limit of blank -LOB) was determined by assaying 24 consecutive replicates of the analyte free (0 level) calibrator on the T60 Clinical Chemistry Analyzer. The LOB was calculated by multiplying the standard deviation by 3 and adding it to the absolute value of the mean. The limit of the blank was calculated to be $1 . 3 ~ \mathrm { u g / m L }$ .

The sponsor conducted a functional sensitivity study to determine the concentration at which acceptable assay precision is observed. A functional sensitivity study was performed using serum samples and the T60 Clinical Chemistry Analyzer. The functional sensitivity was defined as the lowest concentration that can be measured with an inter-assay CV of $20 \%$ . Serum samples were run in duplicates of 4 and the mean and SD were calculated based on the observed results. The sponsor claimed that the functional sensitivity of the candidate device is $3 . 0 \mathrm { u g / m L }$ , the lower limit of the measuring range.

# e. Analytical specificity:

Interference studies were performed using CLSI EP7-A as a guideline. Noninterference was defined as deviations less than or equal to $\pm 1 0 \%$ of the initial value. The results are presented below:

# Carbamazepine:

Bilirubin (total): No interference found up to $5 8 \mathrm { m g / d l }$ Hemolysate: No interference found up to $1 0 0 0 \mathrm { m g / d l }$ Lipemia: No interference found up to $1 0 0 0 \mathrm { m g / d l }$

The sponsor evaluated the specificity of the carbamazepine assay by testing the following compounds:

<table><tr><td colspan="1" rowspan="1">Compound</td><td colspan="1" rowspan="1">ConcentrationTested (μg/ml)</td><td colspan="1" rowspan="1">CarbamazepineConcentration(μg/ml)</td><td colspan="1" rowspan="1">% Cross-reactivity</td></tr><tr><td colspan="1" rowspan="1">Amitryptiline</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">17.7</td><td colspan="1" rowspan="1">18.6</td></tr><tr><td colspan="1" rowspan="1">Carbamazepine-10,11-epoxide</td><td colspan="1" rowspan="1">250</td><td colspan="1" rowspan="1">18.1</td><td colspan="1" rowspan="1">7.4</td></tr><tr><td colspan="1" rowspan="1">Diazepam</td><td colspan="1" rowspan="1">250</td><td colspan="1" rowspan="1">12.0</td><td colspan="1" rowspan="1">4.8</td></tr><tr><td colspan="1" rowspan="1">Imipramine</td><td colspan="1" rowspan="1">200</td><td colspan="1" rowspan="1">11.3</td><td colspan="1" rowspan="1">5.6</td></tr><tr><td colspan="1" rowspan="1">Methsuximide</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">1.0</td></tr><tr><td colspan="1" rowspan="1">Nortriptyline</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">16.4</td><td colspan="1" rowspan="1">17.2</td></tr><tr><td colspan="1" rowspan="1">Phenothiazine</td><td colspan="1" rowspan="1">200</td><td colspan="1" rowspan="1">16.4</td><td colspan="1" rowspan="1">8.6</td></tr><tr><td colspan="1" rowspan="1">Probenecid</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">10.1</td><td colspan="1" rowspan="1">2.0</td></tr></table>

The drugs listed below were spiked into normal human serum pools at the concentrations shown below. The manufacturer indicated that the drug levels evaluated were at a concentrations greater than what would be expected for a maximum daily dose. Results were compared to those of control samples without cross-reactant. The drugs and concentrations tested are shown below. Less than $1 . 0 \%$ cross-reactivity was observed for the following compounds:

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Concentration Tested (μg/ml)</td></tr><tr><td rowspan=1 colspan=1>2-Phenyl-2-ethylmalonamide</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>5-(p-Hydroxyphenyl- phenylhydantoin</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Amobarbital</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Chlorazepate</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Chlordiazepoxide</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Ethosuximide</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Ethotoin</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Glutethimide</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Mephenytoin</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>p-Hydroxyphenobarbital</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Phenytoin</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Primidone</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Promethazine</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Secobarbital</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Valproic Acid</td><td rowspan=1 colspan=1>700</td></tr></table>

Interference studies for valproic acid were performed using CLSI EP7-A as a guideline. The results are presented below:

Valproic Acid:

Bilirubin (total): No interference found up to $5 8 \mathrm { m g / d l }$ Hemolysate: No interference found up to $1 0 0 0 \mathrm { m g / d l }$ Lipemia: No interference found up to $1 0 0 0 \mathrm { m g / d l }$

The following compounds were tested for cross-reactivity in serum samples. Results were compared to those of control samples without crossreactant.

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>ConcentrationTested (μg/ml)</td><td rowspan=1 colspan=1>Valproic AcidConcentration(μg/ml)</td><td rowspan=1 colspan=1>% Cross-reactivity</td></tr><tr><td rowspan=1 colspan=1>3-Hydroxy-2-propylpentanoic acid</td><td rowspan=1 colspan=1>660</td><td rowspan=1 colspan=1>28.8</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>4-Hydroxy-2-propylpentanoic acid</td><td rowspan=1 colspan=1>660</td><td rowspan=1 colspan=1>28.8</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>5-Hydroxy-2-propylpentanoic acid</td><td rowspan=1 colspan=1>660</td><td rowspan=1 colspan=1>38.2</td><td rowspan=1 colspan=1>5.8</td></tr><tr><td rowspan=1 colspan=1>3-Oxo-2-propylpentanoic acid</td><td rowspan=1 colspan=1>1072</td><td rowspan=1 colspan=1>41.2</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=1 colspan=1>PEMA</td><td rowspan=1 colspan=1>1870</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>&lt;0.16</td></tr><tr><td rowspan=1 colspan=1>2-Propyl-2,3-pentadienoic acid</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>42.7</td><td rowspan=1 colspan=1>14.2</td></tr><tr><td rowspan=1 colspan=1>2-Propyl-2-pentanoicacid</td><td rowspan=1 colspan=1>2275</td><td rowspan=1 colspan=1>22.2</td><td rowspan=1 colspan=1>1.0</td></tr><tr><td rowspan=1 colspan=1>2-Propyl-4-pentanoicacid</td><td rowspan=1 colspan=1>278</td><td rowspan=1 colspan=1>62.1</td><td rowspan=1 colspan=1>22.3</td></tr><tr><td rowspan=1 colspan=1>2-Propylglutaric acid</td><td rowspan=1 colspan=1>735</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>&lt;0.4</td></tr><tr><td rowspan=1 colspan=1>2-Propyl-succinic acid</td><td rowspan=1 colspan=1>333</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>&lt;0.9</td></tr><tr><td rowspan=1 colspan=1>Carbamazepine</td><td rowspan=1 colspan=1>7500</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>&lt;0.04</td></tr><tr><td rowspan=1 colspan=1>Carbamazepine-10,11-epoxide</td><td rowspan=1 colspan=1>333</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>&lt;0.9</td></tr><tr><td rowspan=1 colspan=1>Clonazepam</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Diazepam</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Phenobarbital</td><td rowspan=1 colspan=1>7500</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>&lt;0.06</td></tr><tr><td rowspan=1 colspan=1>Phenytoin</td><td rowspan=1 colspan=1>7500</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>&lt;0.04</td></tr><tr><td rowspan=1 colspan=1>Primidone</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>&lt;1.0</td></tr><tr><td rowspan=1 colspan=1>Salicylic acid</td><td rowspan=1 colspan=1>75000</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>&lt;0.004</td></tr></table>

f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device:   
The T60 Carbamazepine assay was compared to the predicate device using CLSI   
Document EP9-A2 as a guideline for the method comparison study. One hundred   
thirty-four serum samples with Carbamazepine values ranging from 1.9 - 19.6   
$\mu \mathrm { g / m L }$ as determined by the predicate device were split and run on the predicate   
and the proposed devices. The regression statistics are as follows:   
Slope $= 0 . 9 8$   
Intercept $= 0 . 0 2 ~ \mu \mathrm { g / m L }$   
Correlation Coefficient $= 0 . 9 9 3$

The T60 Valproic Acid assay was compared to the predicate device using CLSI Document EP9-A2 as a guideline for the method comparison study. One hundred thirty-six serum samples with Valproic Acid values ranging from 3.2 - 143.4

$\mu \mathrm { g / m L }$ as determined by the predicate device were split and run on the predicate   
and the proposed devices. The regression statistics are as follows:   
Slope $= 0 . 9 9 6$   
Intercept $= 1 . 4 ~ \mu \mathrm { g / m L }$   
Correlation Coefficient $= 0 . 9 9 3$

b. Matrix comparison: Not applicable.

a. Clinical Sensitivity: Not applicable.   
b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable; these are quantitative assays.

5. Expected values/Reference range: Carbamazepine A therapeutic range of 4 to $1 2 ~ { \mu \mathrm { g / m L } }$ has been reported for Carbamazepine. See Tietz N. W. Fundamentals of Clinical Chemistry $4 ^ { \mathrm { t h } }$ edition, WB Saunders Co., Philadelphia, PA; 1996; 402-426. Valproic Acid A therapeutic range of 50 to $1 0 0 ~ \mu \mathrm { g / m L }$ has been reported for Valproic Acid. See Tietz N. W. Fundamentals of Clinical Chemistry $4 ^ { \mathrm { t h } }$ edition, WB Saunders Co., Philadelphia, PA; 1996; 402-426.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.